Together, our results demonstrate the efficiency and potency of the newly designed SIK2 inhibitor MRIA9 and confirm the benefit of combining SIK2 inhibition with a taxane-based treatment as a new tumor-suppressing strategy in this highly lethal gynecological disease. Here, SIK2 is linked to female reproductive system disorder.